

August 9, 2019

Foreign Exchange Loss Recorded in the First Quarter

TOKYO, August 9, 2019 - RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TSE-Mothers: 4591, President and CEO: Yoshikazu Nakamura, Ph.D., "RIBOMIC") today announced that a foreign exchange loss was posted as non-operating expenses in the first quarter (April 1, 2019 to June 30, 2019) of the fiscal year ending March 31, 2020.

1. Foreign exchange loss

Due to recent changes in foreign exchange rates, RIBOMIC recorded a foreign exchange loss of 1.335 million yen as non-operating expenses in the first quarter of the fiscal year ending March 31, 2020. The loss is the result of the yen's appreciation during the first quarter and is mainly for foreign currency-denominated assets held by RIBOMIC. The amount of this loss will change depending on upcoming movements in foreign exchange rates.

2. Effect on results of operations

This foreign exchange loss had only a negligible effect on results of operations. As a result, as stated in the Summary of Non-Consolidated Financial Results for the Three Months Ended June 30, 2019, which was announced today (August 9, 2019), there is no revision to the forecast for the fiscal year ending March 31, 2020 that was announced on May 14, 2019.

Contacts for inquiries or additional information:

RIBOMIC Inc.

Corporate Planning Department

ir.inquiry@ribomic.com